President Donald Trump has been heralding drugmakers as “great companies.” Yet in the final stretch of the presidential campaign, Trump is not feeling the love in pharma contributions. Former Vice President Joe Biden is, even though his proposed policies could dent the industry’s profitability.
President Donald Trump is one of at least two dozen people tied to the White House who have tested positive for COVID-19. Negotiations on the next round of COVID relief are off again — maybe. And the FDA and CDC continue to fight for scientific credibility. Alice Miranda Ollstein of Politico, Kimberly Leonard of Business Insider and Erin Mershon of Stat News join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews Amy Howe of SCOTUSblog about what the Supreme Court might do with the latest case challenging the constitutionality of the Affordable Care Act.
During this, the first and only vice presidential debate of the 2020 election season, the two candidates clashed over the coronavirus and other health care issues, as well as a range of other topics.
The president’s doctors have used HIPAA — the Health Insurance Portability and Accountability Act — as a shield to avoid questions about the president’s COVID-19 diagnosis.
The help is real — but access to it isn’t easy.
When in public, President Donald Trump and Vice President Mike Pence join crowded rallies where many do not wear masks. Behind the scenes, the White House is recommending states adopt mask mandates and even fines — leaving it up to local officials to handle the consequences.
Tuesday night’s presidential debate offered voters their first side-by-side comparison of the candidates, President Donald Trump and former Vice President Joe Biden.
The announcement clears the way for Florida and other states to implement a program bringing medications across the border to save money. The effort is strongly opposed by drugmakers and the Canadian government.
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.
The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.
